41 – 50 of 311
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
(
- Contribution to journal › Article
-
Mark
Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients
(
- Contribution to journal › Article
-
Mark
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer : Results from the Prospective, International, Observational Prostate Cancer Registry
(
- Contribution to journal › Article
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
-
Mark
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11
(
- Contribution to journal › Article
-
Mark
Quality of life with pharmacological treatment in patients with benign prostatic enlargement : results from the Evolution European Prospective Multicenter Multi-National Registry Study
(
- Contribution to journal › Article
-
Mark
An Artificial Intelligence-based Support Tool for Automation and Standardisation of Gleason Grading in Prostate Biopsies
(
- Contribution to journal › Article
-
Mark
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) : a structured summary of a study protocol for a randomised controlled trial
(
- Contribution to journal › Letter
-
Mark
The prognostic impact of the tumour stroma fraction : A machine learning-based analysis in 16 human solid tumour types
(
- Contribution to journal › Article